Targeted News Service

Mary Ann Liebert: Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults With Type 1 Diabetes
March 21, 2025

NEW ROCHELLE, New York, March 21 -- Mary Ann Liebert Inc. issued the following news release:

* * *

Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes

New Rochelle, NY, March 20, 2025--A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want an alter . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form